Boston Scientific’s cardiac rhythm management business
In Q2 2018, Boston Scientific’s (BSX) CRM (cardiac rhythm management) sales rose ~3% YoY (year-over-year) to $494 million. It saw operational growth of ~1.2%, compared with ~2.4% in Q1 2018.
Major factors impacting CRM sales
Boston Scientific’s defibrillator portfolio registered high single-digit sales growth in Q2 2018, driven by Resonate and HeartLogic, the only FDA-approved heart failure alert system. The Resonate family of devices received CE[1.European Conformity] marking in February 2017 and FDA approval in May 2017. The company launched the devices in September 2017.
However, the company’s Brady pacing sales fell, registering low-double-digit growth in Q2 2018. It lost market share due to competitive launches and some product gaps in CRT (cardiac resynchronization therapy) pacemakers with MRI (magnetic resonance imaging) and leadless platforms, which the company expects to be a headwind in H2 2018 and aims to address in the near future. However, Boston Scientific expects its CRM business to grow this fiscal year, driven by its defibrillator sales momentum. In the next article, we’ll look at major growth drivers for Boston Scientific’s Electrophysiology business.
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend information. Take a look!